MET
Reactivity: Human, Mouse, Rat
WB, ELISA, IF, ICC
Host: Rabbit
Polyclonal
unconjugated
Application Notes
ELISA: 1/450,000. Western Blot: 1/500 - 1/2,000. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.47 mg/mL (by UV absorbance at 280 nm)
Buffer
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2 containing 0.01 % (w/v) Sodium Azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
AUTS9 antibody, HGFR antibody, RCCP2 antibody, c-Met antibody, AI838057 antibody, HGF antibody, Par4 antibody, Hgfr antibody, c-met antibody, MET antibody, C-MET antibody, met antibody, met-A antibody, MET proto-oncogene, receptor tyrosine kinase antibody, met proto-oncogene antibody, MET proto-oncogene, receptor tyrosine kinase L homeolog antibody, MET antibody, Met antibody, met.L antibody
Background
C-Met is the receptor for hepatocyte growth factor (also known as scatter factor, HGF/SF), and belongs to the tyrosine kinase superfamily. Interaction of c-Met with HGF results in autophosphorylation of c-Met at multiple tyrosines. Phosphorylation of Y1234/1235 in the c-Met kinase domain is critical to kinase activation. When phosphorylated, Y1349 and Y1356, along with surrounding amino acids, form a unique bidentate docking site for substrates such as Gab1, Grb2, phosphatidylinositol 3-kinase (PI3K) and others. C-Met mainly uses the Gab1 scaffolding adaptor in its initial step of signal transmission. Well-characterized downstream signalling pathways that are activated by c-Met include the ERK/MAPK, PI3K-Akt/PKB, Crk-Rap and Rac-Pak pathways, resulting in proliferation and increased cell survival as well as complex motogenic and morphogenic cellular responses. Gene targeting in mice has allowed elucidation of some of the developmental roles of c-Met and HGF/SF, such as their essential function in the formation of skeletal muscle, placenta and liver. Many types of cancer exhibit sustained c-Met stimulation, overexpression, or mutation, including carcinomas of the colon, breast, ovary, lung, liver, prostate, thyroid and kidney, as well as melanomas and sarcomas. In addition to cancer studies, other research areas in which c-Met is under investigation include organogenesis, organ regeneration, angiogenesis and surgical wound healing.Synonyms: HGF/SF receptor, Hepatocyte growth factor receptor, MET, Met proto-oncogene tyrosine kinase, Scatter factor receptor, c-Met